Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases

被引:10
作者
Eduardo, Mariana Bustamante [1 ]
Popovici, Vlad [2 ]
Imboden, Sara [3 ]
Aebi, Stefan [4 ]
Ballabio, Nadja [5 ]
Altermatt, Hans Jorg [6 ]
Gunthert, Andreas [5 ]
Jaggi, Rolf [1 ]
机构
[1] Univ Bern, Dept Biomed Res, Murtenstr 40, CH-3008 Bern, Switzerland
[2] Masaryk Univ, RECETOX, Fac Sci, Brno, Czech Republic
[3] Univ Bern, Bern Univ Hosp, Dept Gynecol & Obstet, Inselspital, Bern, Switzerland
[4] Cantonal Hosp Lucerne, Dept Med Oncol, Luzern, Switzerland
[5] Gyn Zentrum, Breast Ctr Unit, Luzern, Switzerland
[6] Consultarif DRG, Lohn Ammannsegg, Switzerland
关键词
Breast cancer; Molecular risk scores; Local recurrence; Brain metastasis; PAM50; subtypes; Gene expression measurement; Immunohistochemistry; RNA isolation and processing; Hierarchical clustering; DISTANT RECURRENCE; RISK; TAMOXIFEN; CHEMOTHERAPY; SUBCLASSES; PREDICTION; PROGNOSIS; SURVIVAL; PACKAGE; BENEFIT;
D O I
10.1186/s12885-019-5752-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundBreast cancer is a leading cause of cancer-related death in women worldwide. Despite extensive studies in all areas of basic, clinical and applied research, accurate prognosis remains elusive, thus leading to overtreatment of many patients. Diagnosis could be improved by introducing multigene molecular scores in standard clinical practice. Several tests that work with formalin-fixed tissue have become routine. Molecular scores usually include several genes representing processes, response to oestrogens, progestogens and human epidermal growth factor receptor 2 (Her2), respectively, which are combined additively in single values. These multi-gene scores have the advantage of being more robust and reproducible than single-gene scores. Their utility may be further enhanced by combining them with classical diagnostic parameters. Here, we present an exploratory study comparing the RISK and research versions of Oncotype DX recurrence score (RS), Prosigna Risk of Recurrence (ROR) and EndoPredict (EP) with respect to their prognostic potential for ipsilateral recurrence and/or distant relapse in brain, and we compared the scores to the intrinsic subtypes based on PAM50.MethodsRNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue cores of primary tumours, local recurrences and brain metastases. Gene expression was measured on a NanoString nCounter Analysis System. Intrinsic subtypes and molecular scores were computed according to published literature and RISK, RS, ROR and EP were compared against each other and to the intrinsic subtypes Luminal A (lumA), Luminal B (lumB), Her2-enriched (Her2), Basal-like (basal), and Normal-like (normal) of PAM50. Local recurrences and brain metastases were compared to their corresponding primary tumours.ResultsAll four molecular scores were highly correlated. Highest correlations were observed among genes related to proliferation while lower correlations were found among oestrogen-related genes. The scores were significantly higher in primary tumours progressing to brain metastases as compared to recurrence-free primary tumours and primary tumours that relapsed as local recurrences.ConclusionsRISK and ROR-P are prognostic for primary tumours metastasizing to the brain. All four scores, RISK, RS, EP and ROR-P failed to discriminate between primary tumours that remained recurrence-free and primary tumours relapsing as local recurrences.
引用
收藏
页数:14
相关论文
共 38 条
[1]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]   A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer [J].
Alvarado, Michael D. ;
Prasad, Che ;
Rothney, Megan ;
Cherbavaz, Diana B. ;
Sing, Amy P. ;
Baehner, Frederick L. ;
Svedman, Christer ;
Markopoulos, Christos J. .
ADVANCES IN THERAPY, 2015, 32 (12) :1237-1247
[3]   Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue [J].
Antonov, Janine ;
Popovici, Vlad ;
Delorenzi, Mauro ;
Wirapati, Pratyaksha ;
Baltzer, Anna ;
Oberli, Andrea ;
Thuerlimann, Beat ;
Giobbie-Hurder, Anita ;
Viale, Giuseppe ;
Altermatt, Hans Joerg ;
Aebi, Stefan ;
Jaggi, Rolf .
BMC CANCER, 2010, 10
[4]   Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer [J].
Bertucci, Francois ;
Finetti, Pascal ;
Viens, Patrice ;
Birnbaum, Daniel .
CANCER LETTERS, 2014, 355 (01) :70-75
[5]   Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].
Cheang, Maggie C. U. ;
Chia, Stephen K. ;
Voduc, David ;
Gao, Dongxia ;
Leung, Samuel ;
Snider, Jacqueline ;
Watson, Mark ;
Davies, Sherri ;
Bernard, Philip S. ;
Parker, Joel S. ;
Perou, Charles M. ;
Ellis, Matthew J. ;
Nielsen, Torsten O. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750
[6]   A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen [J].
Chia, Stephen K. ;
Bramwell, Vivien H. ;
Tu, Dongsheng ;
Shepherd, Lois E. ;
Jiang, Shan ;
Vickery, Tammi ;
Mardis, Elaine ;
Leung, Samuel ;
Ung, Karen ;
Pritchard, Kathleen I. ;
Parker, Joel S. ;
Bernard, Philip S. ;
Perou, Charles M. ;
Ellis, Matthew J. ;
Nielsen, Torsten O. .
CLINICAL CANCER RESEARCH, 2012, 18 (16) :4465-4472
[7]   Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study [J].
Dowsett, Mitch ;
Cuzick, Jack ;
Wale, Christopher ;
Forbes, John ;
Mallon, Elizabeth A. ;
Salter, Janine ;
Quinn, Emma ;
Dunbier, Anita ;
Baum, Michael ;
Buzdar, Aman ;
Howell, Anthony ;
Bugarini, Roberto ;
Baehner, Frederick L. ;
Shak, Steven .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1829-1834
[8]   Cluster analysis and display of genome-wide expression patterns [J].
Eisen, MB ;
Spellman, PT ;
Brown, PO ;
Botstein, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14863-14868
[9]   A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors [J].
Filipits, Martin ;
Rudas, Margaretha ;
Jakesz, Raimund ;
Dubsky, Peter ;
Fitzal, Florian ;
Singer, Christian F. ;
Dietze, Otto ;
Greil, Richard ;
Jelen, Andrea ;
Sevelda, Paul ;
Freibauer, Christa ;
Mueller, Volkmar ;
Jaenicke, Fritz ;
Schmidt, Marcus ;
Koelbl, Heinz ;
Rody, Achim ;
Kaufmann, Manfred ;
Schroth, Werner ;
Brauch, Hiltrud ;
Schwab, Matthias ;
Fritz, Peter ;
Weber, Karsten E. ;
Feder, Inke S. ;
Hennig, Guido ;
Kronenwett, Ralf ;
Gehrmann, Mathias ;
Gnant, Michael .
CLINICAL CANCER RESEARCH, 2011, 17 (18) :6012-6020
[10]   The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial [J].
Fitzal, F. ;
Filipits, M. ;
Rudas, M. ;
Greil, R. ;
Dietze, O. ;
Samonigg, H. ;
Lax, S. ;
Herz, W. ;
Dubsky, P. ;
Bartsch, R. ;
Kronenwett, R. ;
Gnant, M. .
BRITISH JOURNAL OF CANCER, 2015, 112 (08) :1405-1410